Clinical Trial Update: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating SGN-LIV1A in combination with pembrolizumab for locally advanced or metastatic triple-negative breast cancer. Results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• SGN-LIV1A

Snippet

Sponsor: Seagen Inc. | Conditions: Triple Negative Breast Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-12-12